Molecular Breast Imaging (MBI) is saving lives. Using MBI as an adjunct to mammography results in an almost fourfold increase in invasive cancer detection in women with dense breast tissue. MBI has a higher specificity than MRI and has proven to reduce benign biopsies by 50%. With a negative predictive value of 98% MBI is the beacon in dense breast tissue. Recently, multiple medical centers across the United States have announced the availability of the MBI procedure in their medical practice. Dilon Technologies, a world leader in molecular imaging and inventor of the breast dedicated molecular imaging technology, is proud to announce that the following medical centers will be offering the MBI procedure:

Sentara Rockingham Memorial Hospital (RMH), in Harrisonburg, VA, will obtain the first Discovery NM750b dual head MBI system with Biopsy accessory on the east coast of the United States. Sentara RMH’s robust MBI program commenced in 2007 utilizing the Dilon single head molecular imaging system. “We are excited to now have the ability to biopsy those lesions only seen on MBI, and to expand our MBI program into surgical planning and treatment monitoring,” said Dr. Emily Ritchie, Radiologist at Sentara RMH Medical Center.

Russell County Hospital announced it has purchased and installed Kentucky’s first Discovery NM750b MBI system. “The Molecular Breast Imaging system will better assist our community in early detection of breast cancer,” said Russell County’s Hospital Chief Executive Officer, Bill Kindred. “This technology is an important milestone in Russell County’s longstanding dedication to the fight against breast cancer.”

Fox Chase Cancer Center in Philadelphia, PA, recently announced the addition of the Discovery NM750b MBI system as a complementary diagnostic tool to detect breast cancer after a questionable mammogram. MBI is now available to help physicians in the Philadelphia area detect early stage cancers even in dense breast tissue. “We find MBI with the Discovery NM750b system to be a proven and effective tool in the early detection of breast cancer when mammography is inconclusive,” said Kathryn Evers, MD, FACR, director of mammography at Fox Chase.

The Discovery NM750b is exclusively distributed in North America by Dilon Technologies Inc. The recently FDA‑approved MBI biopsy accessory provides an additional tool to accurately localize the region of interest.

“Dilon can provide the hospital and clinical data references upon request,” according to Pjerin Luli, Dilon’s Director of Sales and Marketing.

With MBI, the patient receives a pharmaceutical tracing agent that is absorbed by all the cells in the body. Due to their increased rate of metabolic activity, cancerous cells in the breast absorb a greater amount of the tracing agent than normal, healthy cells and generally appear as ‘dark spots’ on the MBI image. The Discovery NM 750b MBI system uses revolutionary and leading-edge, solid-state Cadmium Zinc Telluride (CZT) detectors to improve diagnostic accuracy in all types of patients.

DILON Diagnostics and GE Healthcare announce the FDA clearance of the Discovery NM750b MBI breast biopsy accessory

DILON Diagnostics and GE Healthcare are pleased to announce the FDA clearance of the dual head MBI localization accessory for breast biopsy. The Discovery NM750b and the breast biopsy accessory will be presented at the RSNA conference in Chicago, from November 27 to December 1. The Discovery NM750b will be at the Dilon booth number 6132. This important milestone in the breast imaging segment comes shortly after Dilon and GE signed an exclusive agreement for DILON to distribute GE’s Discovery NM750b Molecular Breast Imaging system in North America.    

The Discovery NM750b breast imaging system, designed to measure and image the distribution of selected single photon emission radioisotopes in the human body to aid in the evaluation of lesions, offers clinicians an important tool for imaging of a broad range of patients, including those with dense breast. The MBI localization accessory is a complementary technology to the Discovery NM750b breast imaging system which is designed to accurately locate, in three dimensions, lesions in the breast using information derived from stereotactic pairs of two-dimensional images. It is intended to provide guidance for interventional purposes such as biopsy and pre-surgical.

The power of functional imaging to see and localize early changes is a key factor in early detection of breast cancer.

About DILON Diagnostics

DILON Diagnostics, a brand of DILON Technologies, Inc., located in Newport News, Virginia, designs, manufactures and commercializes innovative medical imaging solutions worldwide.  DILON’s cornerstone product, the DILON Molecular Imaging System, is a high-resolution, compact camera for imaging small body parts, such as the breast, thyroid, parathyroid and bone. The DILON Molecular Imaging System has been optimized to perform Molecular Breast Imaging (MBI/BSGI) procedure that aids in the effective management of suspicious and difficult-to-interpret breast cases. For more information on DILON Diagnostics please visit www.dilon.com

About GE Healthcare

GE Healthcare provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. GE (NYSE: GE) works on things that matter – great people and technologies taking on tough challenges. From medical imaging, software & IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions, GE Healthcare helps medical professionals deliver great healthcare to their patients. For more information visit our website www.gehealthcare.com

Dilon Partners